We are FDA-approved
Its safety with other weight loss products, in individuals who have had pancreatitis, or in children under 18 years of age has not been established In addition to its weight loss benefits, Zepbounds efficacy has been demonstrated in diverse groups: Weight loss in non-diabetics: A 72-week study showed an average weight loss of 15.0% (34 lbs) for the 5 mg dosage, 19.5% (44 lbs) for 10 mg, and 20.9% (48 lbs) for 15 mg Weight loss in diabetics: The same duration study reported an average weight loss of 12.8% (28 lbs) for the 10 mg dosage and 14.7% (33 lbs) for the 15 mg dosage in adults with diabetes While Zepbounds potential for weight management is promising, it is imperative to consider interactions with other medications such as sulfonylureas, insulin, birth control pills, and warfarin
Both Wegovy and Mounjaro are GLP-1 agonists but differ in their specific mechanisms and targets within the body GLP-1 (glucagon-like peptide-1) agonists are a class of medications designed to mimic the effects of the natural hormone GLP-1
Results were that incidence of biliary disease, i.e., conditions that effect the gallbladder/bile ducts, (per 1,000 person-years) was 11.7 for semaglutide, 18.6 for liraglutide (another GLP-1 agonist), and 12.6 for bupropion-naltrexone and 4.6, 7.9 and 1.0, respectively, for pancreatitis
